NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative ...

NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative ...

MS experts are recommending updates to the 2017 McDonald diagnostic criteria that aim to make diagnosis easier, faster and more accurate.

Vancouver, British Columbia--(Newsfile Corp. - August 27, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for ...

NervGen holds exclusive worldwide rights to NVG-291, a first-in-class therapeutic peptide targeting mechanisms that interfere with nervous system repair. NVG-291 is derived from the intracellular ...

We announced to the SCI community that we will cover the cost of travel and accommodation for participants during the 16-week trial," said Mike Kelly, NervGen's President & CEO. "These initiatives are ...

Stifel Nicolaus analyst Justin Keywood maintained a Buy rating on Cipher Pharmaceuticals (CPHRF – Research Report) today and set a price ...

Stifel Nicolaus analyst Justin Keywood maintained a Buy rating on Savaria (SIS – Research Report) today and set a price target of ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.